Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients

Eli O. Meltzer, MD, Judith Rosen Farrar, PhD, and Cary Sennett, MD, PhD

San Diego, Calif; Canandaigua, NY; and Landover, Md

BACKGROUND: Seasonal allergic rhinoconjunctivitis (SARC) affects 216% of the US population annually. Telephone and in-office surveys have demonstrated negative effects of allergic rhinitis (AR) symptoms on sleep, daily activities, productivity, concentration, and emotions.

OBJECTIVE: The objective of this study was to assess the patient-perceived burden of SARC in relation to newer treatments, increased access to treatments, and changing management protocols.

METHODS: An online survey of symptom experience, impact on daily life, and management was conducted in US respondents who suffer (or whose child suffers) from SARC symptoms.

RESULTS: A total of 1001 surveys were completed: 500 adults (≥18 years old) and 501 children (12-17 years old, documented by their parents). Similar to earlier AR surveys, SARC symptoms negatively affected the patient’s (and family’s) quality of life, and were most severe in the spring. Before being treated, >50% of respondents reported daily symptoms during their season; 75% to 80% considered their symptoms moderate to severe. Patients saw a variety of health care professionals (including pharmacists) and used over-the-counter and prescription medications for symptoms. Those using prescription medications were generally more satisfied with treatment and less likely to switch or discontinue treatment. Nasal and/or ocular symptoms drove adherence, seeing a health care professional, and reviewing and/or changing treatment.

CONCLUSIONS: The majority of patients with SARC report moderate-to-severe symptoms that significantly impair their quality of life. However, patients appear to be taking more responsibility for their (child’s) condition, and patient expectations for therapy are increasingly being met. Continued efforts will be needed to examine the contribution of better information and/or increased access to and availability of medications to control the disease. © 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). (J Allergy Clin Immunol Pract 2016;4:411-418).

Key words: Allergic rhinitis; Antiallergic treatment; Nasal/ocular allergy symptoms; Patient perception; Quality of life; Questionnaire; Seasonal allergic rhinoconjunctivitis; Survey

Seasonal nasal and ocular allergy, often referred to as seasonal allergic rhinoconjunctivitis (SARC) and sometimes as “hay
frequently,” is a common chronic disease, estimated to affect upward of 16% of the population of the United States in any one year.1-3 Although estimates of the incidence and prevalence can vary widely depending on the specific population and analyses used,5,4 trends indicate that neither has diminished despite a better understanding of the condition, new pharmacological and immunological treatments, and increased access to care. Indeed, patient-reported and/or physician-diagnosed seasonal nasal and ocular symptoms seem to have become more common.3,5-8 Patients commonly report bothersome symptoms affecting the nose (congestion, sneezing, itching, rhinorrhea) and eyes (itching, redness, watering, swelling) that can vary in frequency, intensity, and seasonality. The underlying mucosal inflammation also can exacerbate other conditions, and symptoms can impair patients’ quality of life (QoL).5,6 For children in particular, symptoms can negatively impact family and daily activities.7 Management requires a multifaceted approach for most individuals, and the patient (and/or parent/caregiver) needs to understand the disease, its variability, and how and when treatment works to optimize clinical outcomes.3,7,8,10 Standard approaches to manage SARC include environmental control methods, pharmacotherapy, and immunotherapy; patient education is critical for day-to-day care.3,10 Discussion of management is beyond the scope of this paper, and readers are directed to several excellent reviews as well as current guidelines.3,7,8,10-12 The goal of treatment is control of the disease, which translates to minimal symptoms and improved well-being and ability to function for the patient (and family).3,6-8,10

Data reported over the past 15 years from surveys of individuals with nasal allergies in the United States and health care professionals (HCPs) who treat those patients in the United States4,8,9,13-17

In previous surveys patients with allergic rhinitis and HCPs reported that:

- The worst season for nasal and eye allergy symptoms was spring.
- The most bothersome symptom was nasal congestion/stuffiness/blocking.
- Nasal and ocular allergy symptoms negatively affected physical and emotional health, daily activities, cognitive ability, and productivity, and contributed to missed work and school days.
- Treatment dissatisfaction was high, and reflected incomplete relief, slow onset of relief, duration of relief less than 24 h, and/or a sense of reduced efficacy with use over time.
- Inadequate efficacy was the primary reason for discontinuing or changing medications.

METHODS

Survey

The survey was conducted online in the United States between March 2 and March 9, 2015, by Nielsen Consumer Insights on behalf of the Asthma and Allergy Foundation of America. The inclusion criteria for survey respondents were as follows:

- Ages 18 years or older
- Personally suffers (or has a child, aged 12-17 years, who suffers) from nasal and/or ocular symptoms of seasonal allergies
- Confirmed by a physician based on the question “Have you been told by a doctor that you have (or your child has) any of the following conditions…” as shown in Appendix E1, available in this article’s Online Repository at www.jaci-inpractice.org
- Has sought treatment from a medical professional for SARC symptoms for themselves or their child in the past year

The survey was designed to be approximately 15 minutes in length and to obtain information on patient and/or parent perspectives of the burden of nasal and ocular seasonal allergy symptoms occurring at a time when they (their child) typically experienced symptoms (as opposed specifically to the week of survey administration). Survey design was similar to earlier phone surveys5,9,13-17 but updated given the availability of newer prescription and OTC medications since those surveys were conducted. The survey is shown in Appendix E1, available in this article’s Online Repository at www.jaci-inpractice.org.

Sample source

The sample source was derived from a Harris Poll panel of respondents for online consumer research supplemented by similar online panels from various Nielsen research partners. The sample was pulled randomly to provide a national census representation of respondents who met the inclusion criteria. To efficiently screen for parents of children with SARC, individuals preidentified from known panel statistics as parents of children (<18 years) were targeted.

Email invitations were sent to a total of 79,839 potential respondents with a password protected link, so that each link could only be used once.

### Table I. Key outcomes of phone and paper surveys of patients with allergic rhinitis and health care professionals (HCPs) who treat those patients in the United States

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Patients</th>
<th>HCPs</th>
</tr>
</thead>
<tbody>
<tr>
<td>The worst season for nasal and eye allergy symptoms was spring.</td>
<td>Nasal and ocular allergy symptoms negatively affected physical and emotional health, daily activities, cognitive ability, and productivity, and contributed to missed work and school days.</td>
<td>Treatment dissatisfaction was high, and reflected incomplete relief, slow onset of relief, duration of relief less than 24 h, and/or a sense of reduced efficacy with use over time.</td>
</tr>
<tr>
<td>The most bothersome symptom was nasal congestion/stuffiness/blocking.</td>
<td>Inadequate efficacy was the primary reason for discontinuing or changing medications.</td>
<td></td>
</tr>
<tr>
<td>Nasal and ocular allergy symptoms negatively affected physical and emotional health, daily activities, cognitive ability, and productivity, and contributed to missed work and school days.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Abbreviations used

- AR - Allergic rhinitis
- HCP - Health care professional
- INAH - Intranasal antihistamine
- INCS - Intranasal corticosteroid
- OTC - Over the counter
- QoL - Quality of life
- SARC - Seasonal allergic rhinoconjunctivitis

### Sample source

The sample source was derived from a Harris Poll panel of respondents for online consumer research supplemented by similar online panels from various Nielsen research partners. The sample was pulled randomly to provide a national census representation of respondents who met the inclusion criteria. To efficiently screen for parents of children with SARC, individuals preidentified from known panel statistics as parents of children (<18 years) were targeted.

Email invitations were sent to a total of 79,839 potential respondents with a password protected link, so that each link could only be used once.
دریافت فوری متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات